Expand ABOS Menu
ABOS MENU

ABOS Latest Press Releases

-- December 2, 2025 --

Acumen Pharmaceuticals Highlights Enhanced Brain Delivery Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference Globe Newswire 8:00 AM

-- November 18, 2025 --

Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference Globe Newswire 8:00 AM

-- November 17, 2025 --

Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer's Disease Globe Newswire 8:00 AM

-- November 12, 2025 --

Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights Globe Newswire 7:00 AM

-- November 10, 2025 --

Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors Globe Newswire 8:00 AM

-- November 5, 2025 --

Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025 Globe Newswire 4:00 PM

-- November 4, 2025 --

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference Globe Newswire 4:00 PM

-- August 26, 2025 --

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences Globe Newswire 4:00 PM

-- August 12, 2025 --

Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights Globe Newswire 7:00 AM

-- August 5, 2025 --

Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025 Globe Newswire 4:00 PM

-- July 28, 2025 --

Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer's Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer's Association International Conference (AAIC) 2025 Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes